Osterix (Osx) is a transcription factor required for osteoblast differentiation and bone formation. We previously demonstrated that continuous parathyroid hormone (PTH) treatment inhibited Osx expression in murine calvaria and osteoblastic UMR106-01 cells through the regulation of two regions on the Osx promoter. Mutational analysis of transcription factor elements within these regions revealed two "Sp-sites" were vital for Osx promoter activity. Blockage of these Sp-sites with Mithramycin A demonstrated their importance for Osx expression. Osx bound to its own promoter at these sites, while PTH treatment inhibited this association. PTH regulation of Osx expression in vivo was investigated in mice by: daily injection of PTH for 3 days, continuous infusion of PTH from osmotic pumps for 14 days, or mice fed a calcium-deficient diet for 21 days. Osx expression was decreased by daily injection, while Osx expression was stimulated in mice receiving continuous PTH infusion and mice fed a calcium-deficient diet.

Osterix (Osx) is a transcription factor required for osteoblast differentiation and bone formation. We previously demonstrated that continuous parathyroid hormone (PTH) treatment inhibited Osx expression in murine calvaria and osteoblastic UMR106-01 cells through the regulation of two regions on the Osx promoter. Mutational analysis of transcription factor elements within these regions revealed two "Sp-sites" were vital for Osx promoter activity. Blockage of these Sp-sites with Mithramycin A demonstrated their importance for Osx expression. Osx bound to its own promoter at these sites, while PTH treatment inhibited this association. PTH regulation of Osx expression in vivo was investigated in mice by: daily injection of PTH for 3 days, continuous infusion of PTH from osmotic pumps for 14 days, or mice fed a calcium-deficient diet for 21 days. Osx expression was decreased by daily injection, while Osx expression was stimulated in mice receiving continuous PTH infusion and mice fed a calcium-deficient diet.

Ulm, Univ. Diss., 2006.

Zugl.: Freiburg (Breisgau), Universiẗat, Diss., 2008.

Jena, Universiẗat, Diss., 2008.

Ulm, Univ., Diss., 2001.

Osteoblasts and osteoclasts are crucial to maintaining bone homeostasis. These specialized cells rely on various environmental signals and cross talk from one another in order to model, remodel and repair bone. Exogenous chemicals such as the therapeutic drug rosiglitazone, a peroxisome proliferator activated receptor gamma (PPARγ) agonist, can interfere with bone-forming and bone-resorbing pathways, causing osteoporosis and increasing the risk of bone fracture. Evidence is emerging that environmental toxicants induce similar toxic endpoints in bone, both through PPARγ-dependent and PPARγ-independent mechanisms. To date, these toxicants have only ever been considered in isolation or in limited co-exposure studies. This comprehensive review relating these toxicants and their effect on bone health will help guide future studies and illuminate gaps in our knowledge. Five toxicant classes (organotins—mainly tributyltin; TBT, heavy metals—lead, cadmium, and arsenic, dioxin-like chemicals, phthalates, and perfluoroalkyl compounds; PFAs) were examined, with emphasis on molecular targets, osteoclast- and osteoblast-specific effects, animal models and epidemiological data. It was concluded that organotins (TBT) act via PPARγ and RXR agonism, phthalates act via PPARγ agonism, heavy metals act at least through ERK-mediated pathways, and dioxin-like chemicals act through aryl hydrocarbon receptor interaction. The molecular targets of PFAs remain unknown. Additional targets are still being investigated. These findings emphasize the importance of co-exposures, as these toxicants act through diverse molecular mechanisms that may share toxic endpoints, making co-exposure consequences particularly severe. While the evidence available strongly suggests that lead, cadmium, and dioxin-like chemicals are negative modulators of human bone health, evidence supporting this conclusion for organotins, phthalates, arsenic, and PFAs is somewhat lacking. There are still significant gaps in our understanding that must be filled to gain a holistic understanding of these threats to human bone health.

Glucocorticoids are widely used as anti-inflammatory and chemotherapeutic agents. However, prolonged use of glucocorticoids leads to osteoporosis. This study was designed to examine the mechanism of dexamethasone (DEX)-induced apoptosis in murine osteoblastic MC3T3-E1 cells. Total RNA was extracted from MC3T3-E1 cells treated with 10-7 M DEX for 6 h. DEX exerted a variety of effects on apoptotic gene expression in osteoblasts. Ribonuclease protection assays (RPA) revealed that DEX upregulated mRNA levels of caspases-1, -3, -6, -8, -11, -12, and bcl-XL. Western blot analysis showed enhanced processing of these caspases, with the appearance of their activated enzymes 8 h after DEX treatment. In addition, DEX also induced the activation of caspase-9. DEX elevated the levels of cleaved poly(ADP-ribose) polymerase and lamin A, a caspase-3 and a caspase-6 substrate, respectively. Expression of bcl-XL protein level was upregulated by DEX. Cytochrome c release was detected in the cytosol of DEX-treated cells. Furthermore, caspase-3 enzyme activity was elevated by 2-fold after DEX treatment for 7 h. Finally, early apoptotic cells were detected in cells treated with DEX for 3 h. Our results demonstrate that DEX-induced apoptosis involves gene activation of a number of caspases.

Indiana University-Purdue University Indianapolis (IUPUI) / Many factors are present in the development of skeletal tissue. Some factors lead to an increase in bone mass while some lead to a decrease. One factor that is known to have an influence on skeletal development is Signal Transducer and Activator of Transcription 3 (Stat3). This knowledge arose because of a mutation in the Stat3 gene in humans causing a disease called Hyper-IgE Syndrome. This mutation leads to a variety of issues, including decreased bone mass. Because of this, our lab has sought to study Stat3 in its relation to bone. Many studies have already been conducted that discern how Stat3 influences skeletal biology by observing its role in osteoclasts, osteoblasts, and other bone cells. Its role is still unclear, and many studies have provided seemingly contradictory results in how it works on bone tissue. Our lab set up several different studies in order to further elucidate what role Stat3 plays in skeletal development by looking at its effects on osteoblasts and osteoclasts, the bone-forming and bone-destroying cells of the body, respectively. We conditionally knocked out Stat3 in the osteoblasts of mice and compared several different bone parameters to their wild type counterparts at 8 weeks of age. Differences were noted in bone phenotype, including decreased femur length, weight, bone mineral density, and bone mineral content in the cKO compared to their WT counterparts. While no significant difference in trabecular integrity was noted, several differences were observed in cortical bone. These differences indicate that Stat3 has a positive role in osteoblast differentiation, leading to an overall positive effect on bone mass. To observe the role of Stat3 in osteoclasts, in vitro experiments were set up in which pre-osteoclast RAW 264.7 cells were manipulated with Stat3 siRNA or a Stat3 overexpression construct and RANKL to induce differentiation. Using qPCR and western blot assays, it was determined that when Stat3 is knocked down, several important genes in osteoclastogenesis and osteoclast function are more highly expressed than in the control groups. When Stat3 is overexpressed, a similar pattern is observed where these same genes are downregulated in the presence of higher Stat3 levels. These results indicate that Stat3 has an overall inhibitory effect on osteoclastogenesis and osteoclast function, indicating it has a positive effect on bone mass. Future studies could be performed to further elucidate the effects of Stat3 on skeletal development. Isolating the osteoblasts from cKO and WT mice and performing qPCR and western blot assays could be useful in finding out how Stat3 is influencing these cells. Further studies could also be done on the RAW 264.7 cells to find where Stat3 is interacting with the RANKL pathway. A resorption assay could be done with these cells to better understand how function might be influenced by Stat3.

Bei der Implantatversorgung von Patienten mit Osteoporose besteht weiterhin eine hohe Komplikationsrate vor allem durch aseptische Prothesenlockerungen. Eine vielversprechende Möglichkeit diese zu minimieren stellt eine Funktionalisierung der Implantate mit Strontium dar. Ziel der vorliegenden Arbeit war es dabei die Wirkung lokal verfügbaren Strontiums auf osteoklastäre und osteoblastäre Zellen zu untersuchen. Mittels elektrochemischer Abscheidung erfolgte die Beschichtung von Titanproben mit strontiumdotiertem Struvit, wobei sieben verschiedene Dotierkonzentrationen zwischen 6 µg und 487 µg Strontium pro Probe hergestellt wurden. Die Untersuchungen an osteoklastären RAW 264.7 Zellen erfolgten mittels Bestimmung von Zellzahl und -aktivität, verschiedener mikroskopischer Methoden sowie auf genetischer Ebene. Osteoblastäre MG63-Zellen wurden orientierend anhand von Zellzahl und Zellaktivität untersucht. Zellbiologisch konnte ein hemmender Einfluss von Strontium auf Differenzierung sowie Proliferation und Aktivität osteoklastärer Zellen gezeigt werden. Die Dotierkonzentration mit den günstigsten Eigenschaften war unter vorliegenden Versuchsbedingungen 487 µg Strontium pro Probe, da sich hierbei zudem eine erhaltene ostoblastäre Proliferation und Aktivität zeigte. / Aseptic loosening of implants is still an issue especially for patients with osteoporosis. In order to minimize the risk of implant failure the functionalisation of implant surfaces with strontium is a promising technique. The aim of the present study was to investigate the effect of locally availible strontium on osteoclastic and osteoblastic cells. Electrochemically assisted deposition was used to provide strontium substituted struvite coatings on titanium surfaces. The strontium concentration ranged from 6 µg to 487 µg per sample. Growth of osteoclastic cells was investigated by the determination of cell number and cellular activity, as well as microscopical and transcriptional level studies. Osteoblasts were studied by determining cell number and cell activity. A general suppressing influence of strontium was observed on the differentiation and activity of osteoclasts. The most favourable properties were found for the highest strontium concentration under investigation, because additionally cell proliferation and activity of osteoblasts was not significantly affected.